for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Newron Pharmaceuticals SpA

NWRN.S

Latest Trade

2.02CHF

Change

0.09(+4.40%)

Volume

29,375

Today's Range

1.90

 - 

2.02

52 Week Range

1.65

 - 

3.06

As of on the SIX Swiss Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
1.93
Open
1.99
Volume
29,375
3M AVG Volume
0.42
Today's High
2.02
Today's Low
1.90
52 Week High
3.06
52 Week Low
1.65
Shares Out (MIL)
17.85
Market Cap (MIL)
35.96
Forward P/E
-1.81
Dividend (Yield %)
--

Latest Developments

More

Newron H1 Net Loss Narrows To EUR 9.1 Mln

Newron Initiates First Study In Patients With Schizophrenia

Newron Announces Paragraph IV ANDA Filings For XadagoIn The U.S.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Newron Pharmaceuticals SpA

Newron Pharmaceuticals SpA is an Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The Company undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson’s disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Its additional projects, such as HF0220 for neuroprotection, NW-3509 for the treatment of schizophrenia, as well as pruvanserin and sarizotan for treatment of CNS diseases, are at various stages of preclinical and clinical development.

Industry

Biotechnology & Drugs

Contact Info

via Ludovico Ariosto 21

20091

Italy

+39.02.6103461

https://www.newron.com/

Executive Leadership

Ulrich Kostlin

Chairman, Non-Executive Director

Stefan Weber

Chief Executive Officer, Executive Director

Roberto Galli

Vice President Finance

Dennis Dionne

Vice President Commercial Affairs

Marco Caremi

Executive Vice President Business Development

Key Stats

1.33 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (EUR)

2018

-0.840

2019

-1.130

2020

-1.180

2021(E)

-1.040
Price To Earnings (TTM)
--
Price To Sales (TTM)
6.20
Price To Book (MRQ)
3.87
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
310.37
LT Debt To Equity (MRQ)
308.56
Return on Investment (TTM)
-43.68
Return on Equity (TTM)
-40.03

Latest News

Latest News

BRIEF-Newron Pharmaceuticals To Prioritize Its Phase III Development Program Of Evenamide In Schizophrenia

* REPORTS TOP-LINE RESULTS FROM ITS STARS STUDY EVALUATING SARIZOTAN IN PATIENTS WITH RETT SYNDROME

BRIEF-Newron Receives Third Tranche From Financing Agreement With European Investment Bank

* NEWRON RECEIVES THIRD TRANCHE FROM FINANCING AGREEMENT WITH EUROPEAN INVESTMENT BANK (EIB)

BRIEF-Newron cannot predict how long coronavirus will delay schizophrenia trial

* ANTICIPATES A DELAY IN START OF ITS PLANNED STUDIES WITH EVENAMIDE IN SCHIZOPHRENIA DUE TO HOSPITAL STAFF BEING SHIFTED TO CORONAVIRUS CASES, AWAY FROM RESEARCH

BRIEF-Newron Updates On STARS Study FDA Interaction

* NEWRON PHARMACEUTICALS SPA - RECEIVED FINAL MINUTES FROM MEETING WITH U.S. FDA HELD ON FEB. 5, 2020

BRIEF-Newron Pharmaceuticals FY Net Loss Widens To EUR 20.2 Million

* NEWRON PHARMACEUTICALS SPA - IN 2019, NEWRON REPORTED A NET LOSS OF EUR 20.2 MILLION, COMPARED TO EUR 15.0 MILLION IN 2018. Source text for Eikon: Further company coverage: (Gdansk Newsroom)

BRIEF-Newron Starts Clinical Trial With Evenamide In Schizophrenia Patients

* ANNOUNCES INITIATION OF NEW CLINICAL TRIAL WITH EVENAMIDE IN PATIENTS WITH SCHIZOPHRENIA, FOLLOWING APPROVAL OF PLAN BY FDA

BRIEF-Newron Pharmaceuticals To Request Type A FDA Meeting

* NEWRON PHARMACEUTICALS TO REQUEST TYPE A FDA MEETING PRIOR TO UNBLINDING OF STARS CLINICAL TRIAL DATA

BRIEF-Newron Pharmaceuticals SpA Gets Second Tranche From Financing Agreement

* NEWRON RECEIVES SECOND TRANCHE FROM FINANCING AGREEMENT WITH EUROPEAN INVESTMENT BANK (EIB) Source text for Eikon: Further company coverage:

BRIEF-Newron Receives FDA Rare Pediatric Disease Designation For Sarizotan

* NEWRON RECEIVES FDA RARE PEDIATRIC DISEASE DESIGNATION FOR SARIZOTAN FOR THE TREATMENT OF RETT SYNDROME Source text for Eikon: Further company coverage:

BRIEF-Newron Pharmaceuticals Says FDA Grants Rare Pediatric Disease Designation For Sarizotan

* U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS GRANTED RARE PEDIATRIC DISEASE DESIGNATION FOR SARIZOTAN Source text https://bit.ly/2KxxDXW Further company coverage: (Gdansk Newsroom)

BRIEF-Newron Pharmaceuticals H1 Net Loss Widens To EUR 14.0 Mln

* H1 NET LOSS OF EUR 14.0 MILLION, COMPARED TO EUR 7.6 MILLION IN SAME PERIOD IN 2018 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Newron: Zambon And Valeo Pharma Launch Onstryv For Parkinson's disease In Canada

* DGAP-NEWS: NEWRON'S COMMERCIALIZATION PARTNER ZAMBON AND VALEO PHARMA ANNOUNCE THE LAUNCH OF ONSTRYV(R) (SAFINAMIDE) FOR PARKINSON'S DISEASE IN CANADA Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Newron Pharmaceuticals Reiterates Guidance

* REITERATES GUIDANCE IT GAVE AT FULL YEAR RESULTS ON MARCH 5, 2019 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Newron delays schizophrenia drug trial after FDA raises concerns

Swiss-listed drugmaker Newron must delay a trial of its prospective schizophrenia medicine evenamide after the U.S. Food and Drug Administration raised concerns about central nervous system (CNS) events that have emerged in rats and dogs.

BRIEF-Newron Pharmaceuticals Provides Update On Regulatory Status Of Evenamide

* PROVIDES UPDATE ON REGULATORY STATUS OF EVENAMIDE FOR TREATMENT OF SCHIZOPHRENIA

BRIEF-Newron Pharmaceuticals FY Net Loss Widens To EUR 15.04 Million

* FY TOTAL REVENUES DECREASED TO EUR 4.0 MILLION FROM EUR 13.4 MILLION (2017)

BRIEF-Newron Completes Patient Enrollment In Pivotal STARS Study

* POSITIVE STUDY RESULTS MAY LEAD TO APPROVAL OF FIRST DRUG TO BENEFIT A KEY SYMPTOM OF RETT SYNDROME, A SEVERE NEURO-DEVELOPMENTAL ORPHAN DISEASE Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Newron Pharmaceuticals: Commercialization Partner Zambon With Valeo Pharma Announce Approval Of Onstryv® (Safinamide) For Parkinson’S Disease In Canada

* NEWRON PHARMACEUTICALS: COMMERCIALIZATION PARTNER ZAMBON TOGETHER WITH VALEO PHARMA ANNOUNCE THE APPROVAL OF ONSTRYV® (SAFINAMIDE) FOR PARKINSON’S DISEASE IN CANADA Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Newron Pharmaceuticals: Zambon Announces Approval And ARTG Listing Of Safinamide In Australia

* ZAMBON ANNOUNCES APPROVAL AND ARTG LISTING OF SAFINAMIDE IN AUSTRALIA FOR TREATMENT OF PATIENTS WITH PARKINSON'S DISEASE Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up